Back to Search
Start Over
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.
- Source :
-
Journal of gastroenterology [J Gastroenterol] 2015 Jun; Vol. 50 (6), pp. 667-74. Date of Electronic Publication: 2014 Sep 11. - Publication Year :
- 2015
-
Abstract
- Background: This study examined the effects of peretinoin, an acyclic retinoid, on the survival of patients with hepatitis C virus-related hepatocellular carcinoma (HCC) who had completed curative therapy and participated in a randomized, placebo-controlled trial.<br />Methods: This study was an investigator-initiated retrospective cohort study. Subjects were all patients who were administered the investigational drug (peretinoin 600 mg/day, peretinoin 300 mg/day, or placebo) in the randomized trial. Survivals between the groups were compared using the log-rank test, and hazard ratios were estimated by Cox regression.<br />Results: Survey data were collected from all patients (n = 392) who participated in the randomized trial, all of whom were then divided into the peretinoin 600 mg/day (n = 132), peretinoin 300 mg/day (n = 131), and placebo (n = 129) groups. At the median follow-up of 4.9 years, 5-year cumulative survival rates for patients in the 600 mg/day, 300 mg/day, and placebo groups were 73.9, 56.8, and 64.3 %, respectively. Comparison of overall survival among patients classified as Child-Pugh A revealed that survival of the 600 mg/day group (n = 105) was significantly longer than that of the placebo group (n = 108) (hazard ratio 0.575, 95 % CI 0.341-0.967; P = 0.0347).<br />Conclusions: Administration of 600 mg/day peretinoin to patients with hepatitis C virus-related HCC who have completed curative therapy may improve survival for those classified as Child-Pugh A, for whom liver function is relatively stable.
- Subjects :
- Aged
Anticarcinogenic Agents administration & dosage
Anticarcinogenic Agents therapeutic use
Carcinoma, Hepatocellular pathology
Carcinoma, Hepatocellular virology
Cohort Studies
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Liver Neoplasms pathology
Liver Neoplasms virology
Male
Proportional Hazards Models
Randomized Controlled Trials as Topic
Retinoids administration & dosage
Retrospective Studies
Survival Rate
Carcinoma, Hepatocellular drug therapy
Hepatitis C complications
Liver Neoplasms drug therapy
Retinoids therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1435-5922
- Volume :
- 50
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 25209978
- Full Text :
- https://doi.org/10.1007/s00535-014-0996-1